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1. Introduction
Smith-Magenis syndrome (SMS) is a rare developmental disorder featuring impaired intellectu‐
al and behavioral abnormalities. SMS is still not well known because it is characterized by subtle
facial dysmorphology that progresses with age, and clinical features that overlap with other
intellectual disability syndromes as Prader–Willi, Williams-Beuren, and Down syndromes. Due
to their intellectual impairment especially their abnormal and frequently anti-social behavior,
most individuals affected with SMS are institutionalized without proper diagnosis and care.
2. Background
Patients with the features of SMS were first described in 1982 by Ann C.M. Smith in an ab‐
stract presented at the Annual Meeting of the American Society of Human Genetics [1]. In 1986,
Ellen Magenis together with Ann C.M. Smith and their colleagues published a clinical review
of nine individuals affected by this nosologic entity. For this reason the syndrome was named
after them [2]. A deletion of chromosome 17p11.2 was identified as the cause of this condition
in approximately 90% of cases, and thus this disorder belongs to the group of contiguous-gene
syndromes, currently referred to as genome diseases [3-5]. SMS patients without deletions
17p11.2 may carry a point mutation in the gene RAI1 [6-10], which codes a transcription factor
acting in several different biological pathways. RAI1 dosage is crucial for normal regulation of
circadian rhythm, lipid metabolism, and melatonin function. SMS affects both sexes equally and
has been found in all ethnic groups. The incidence of SMS was initially estimated at 1:25,000
births [11]. However improvements in cytogenetic techniques and molecular analyses have
allowed the diagnosis of most cases, leading to a current prevalence estimate of 1:15,000 [12].
© 2013 Moretti-Ferreira; licensee InTech. This is an open access article distributed under the terms of the
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unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
3. Clinical characteristics
SMS dysmorphysms change with age. The most common facial characteristics of the syndrome
include broad square-shaped face, brachycephaly, prominent forehead, synophrys, deep-set
eyes, broad nasal bridge, midface hypoplasia, micrognathia in infancy, relative prognathism
with age, and everted, "tented" upper lip [13]. Dental anomalies such as premolar agenesis and
taurodontism have also been reported [14].
Individuals  with SMS show mild to  moderate  mental  retardation [11,  15],  and behavio‐
ral  abnormalities  such  as  sleep  disturbances,  stereotypic  movement,  and  self-injurious
behavior  [16-21].
To date, nearly two hundred cases have been described in the literature. In 2011 Gamba and
colleagues presented seven Brazilian cases and a meta-analysis of clinical signs in SMS






N = 165 Fisher's Exact test
Craniofacial % P value
Brachycephaly 5/7 95/106 89.6 0.1893
Microcephaly 3/7 9/56 16.0 0.1199
Midface Hypoplasia 6/7 87/10 79.8 1.0000
Broad, square-shaped face 7/7 64/82 78.0 0.3367
Broad Nasal Bridge 7/7 41/51 80.39 0.3356
Short Philtrum 7/7 11/11 100.00 1.0000
Everted, "tented" upper lip 6/7 64/83 77.11 1.0000
Cleft lip/palate 0/7 12/47 25.53 0.3275
Relative prognathism with age 6/7 49/62 79.03 1.0000
Micrognathia 1/7 12/28 42.86 0.2197
Skeletal
Short stature 6/7 35/71 49.30 0.1115
Scoliosis 3/7 23/53 43.40 0.6971
Dental anomalies 7/7 4/11 36.36 0.0128
Short broad hands 7/7 n/a n/a
Clinodactyly 6/7 19/30 63.33 0.3891
Brachydactyly 7/7 67/81 82.72 0.5915
Syndactly 5/7 15/50 30.00 0.0837
Ocular abnormalities
Deep-set, close-spaced eyes 6/7 47/72 65.28 0.4156
Synophrys 5/7 31/57 54.39 0.4540






N = 165 Fisher's Exact test
Strabismus 7/7 39/67 58.21 0.0400
Iris Abnormalities 5/7 10/23 43.48 0.3898
Otoryngological
Ear Abnormalities 4/6 48/76 63.16 0.6938
Ear infections 2/7 28/36 77.78 0.0190
Hoarse, deep voice 1/7 40/52 76.92 0.0023
Hearing loss 3/7 46/74 62.16 0.4258
Neurological
Cognitive impairment/developmental
delay 7/7 100/100 100.00 1.0000
Speech delay 7/7 101/111 90.99 1.0000
Motor Delay 7/7 92/114 80.70 0.3479
Infantile hypotonia 4/7 49/77 63.64 0.7054
Sleep disturbance 5/6 97/110 88.18 0.5462
Hyporeflexia 1/7 2/4 50.00 0.4909
Behavior
Self-Hung 7/7 17/20 85.00 1.0000
Onychotillomania 5/7 15/24 62.50 1.0000
Polyembolokoilamania 6/7 14/23 60.87 0.3717
Head Banging/Face Slapping 1/2 36/43 83.72 0.3273
Hand Biting 4/5 19/19 100.00 0.2083
Attention Seeking 5/5 52/54 96.30 1.0000
Aggressive behavior 7/7 62/67 92.54 1.0000
Self-injurious behaviors 7/7 56/61 91.80 1.0000
Hyperactivity 6/7 52/54 96.30 1.0000
Other features
Cardiac defects 0/7 44/88 50.00 0.0139
Renal/urinary tract abnormalities 1/7 12/49 24.49 1.0000
EEG abnormal/ evident seizures 3/5 23/58 39.66 0.6687
Hypogonadism male 1/7 21/60 35.00 0.4116
Obesity 3/7 12/51 23.53 0.3597
Bold type Statistically significant values of P less than 0.05 (two-tailed Fisher exact test).
(+) positive (-) negative (n/a) not available
Table 1. Clinical features of seven Brazilian Smith-Magenis syndrome cases and meta-analysis of 165 cases from the
literature (Gamba et al., Genet. Mol. Res. 10 [4]: 2664-2670, 2011, Published with permission from Genetics and
Molecular Research-Online Journal) [22].
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3.1. SMS features in infancy, childhood/adolescence and adulthood
3.1.1. Infancy
The gestation of children with SMS is commonly uneventful. When maternal report is
available, a diminution of fetal movements is described in 50% of cases. At birth all parameters
(weight, length, OFC) are normal, including time of gestation.
The occurrence of generalized hypotonia and hyporeflexia promotes a marked oral motor
dysfunction, with poor sucking and swallowing, and gastroesophageal reflux. Failure to thrive
is attributed to feeding difficulties. During the first year of life, parents often describe SMS
cases as perfect babies because they sleep very well and cry little.
Behavior disturbances can be observed as early as 4 months. Videotape analysis shows
patients’ motor repertoire is significantly reduced, and fidgety general movements, which are
typical of that age, are missing. Posture is abnormal and overall movements are jerky and
monotonous. These findings indicate a severe motor impairment as early as 4 months of age
[23]. Beyond 18 months, signs of developmental delay become increasingly obvious, with early
stages of intense crying and sleepless nights. Within 2-3 years of age patients have a clear delay
in language acquisition, with lalation [24-25]. Dysmorphic signs subsequently begin to become
more evident, with facial hypotonia, and relative micrognathia.
3.1.2. Childhood/adolescence
It is at this stage of life that patients with SBS have dysmorphisms, significant cognitive delays
and a peculiar behavior and come to the attention of health professionals. Most patients are
diagnosed at this stage of life.
Facial dysmorphisms include broad and square-shaped face, mild face hypoplasia, brachice‐
phaly, short nasal philtrum, a tendency toward an everted upper lip, and relative prognathism.
Patients may present with short stature, scoliosis, dental abnormalities, and brachydactyly
with clinodactyly at 5th and digital syndactyly between the 3th and 4th toe. Ocular abnor‐
malities may be present, such as deep-set eyes and close-spaced, synophrys, strabismus and
iris abnormalities. The main otoryngological alterations are recurrent ear infections resulting
in hearing loss, middle/inner ear abnormalities and deep hoarse voice.
Cognitive impairment and developmental delay are pronounced, however the most pro‐
nounced neurological alteration is sleep modifications. Patients with SMS often exchange
nocturnal sleep for daytime naps, with changes of the circadian cycle and alterations in the
release of melatonin [26-28].
Alterations of behavior are atypical and draw the most attention, because they are often unique
to patients with SMS. Besides hyperactivity and attention seeking, patients with SMS may
present agressive and self-injurious behavior, including hand biting, head banging, face
slapping, self-hanging, onychotilomania and polyembolokotonia [16,19, 29-35]. Other signs
reported in up to 50% of patients include obesity, cardiacs defects, seizures, cleft lip/palate and
male hypogonadism [22].
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Figures 1-7 are patients diagnosed with SMS in Genetic Counseling Service Dept Genetics. IBB/
UNESP- Botucatu, Brazil, and several of these patients were published (Published with
permission from Genetics and Molecular Research-Online Journal, Gamba et al., 2011. Genet. Mol.
Res. 10 [4]: 2664-2670 ).
 
Figure 1. Patient 1. – 8.25 years-old
 
Figure 2. Patient 2 – 18.83 years-old
 
Figure 3. Patient 3. – 12.83 years-old
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 Figure 4. Patient 4 – 12.83 years-old
 
Figure 5. Patient 5. – 13.33 years-old
 
Figure 6. Patient 6 – 19.0 years-old
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 Figure 7. Patient 7. – 20.58 years-old
3.1.3. Adulthood
Adults  with  SMS  have  a  diminution  of  stereotypic  movements,  but  when  frustrated,
develop  aggressive  speech,  with  shouting  or  profanity  at  high  volume.  Little  data  is
published regarding the life expectancy of patients with SMS. However it is believed that
life  expectancy is  normal  or  similar  to  that  of  other  individuals  with  the  same level  of
cognitive dysfunction [36,37].
4. Genetics
Most cases of SMS are caused by a microdeletion on 17p11.2 that encompasses multiple genes,
including the retinoic acid-induced 1, RAI1, gene. This deletion is observed in 90% of the cases,
although in 10% of cases a point mutation in the RAI1 gene is observed [2, 4, 6, 20, 38]. SMS
microdeletions are caused by irregularities in chromosomal recombination mediated by repeat
elements referred to as Low copy number repeats (LCR). Already [39] identified three copies
of an LCR as being responsible for the deletion on 17p11.2. These repeats (LCRs proximal,
middle, and distal - SMS REPs) form substrates for inter- and intrachromosomal recombina‐
tion. In 70% of SMS cases, unequal meiotic crossovers result in nonallelic homologous
recombination between the proximal and distal SMS REPs and a deletion of approximately
3.7Mb. In the remaining 30%, deletions are due to alternate SMS REPs (distal x medial).
Moreover, AT-rich repeats and Alu elements may act as homologous recombination substrates,
and nonhomologous mechanisms can generate deletions of atypical deletions sizes [40-42].
5. Diagnosis
SMS is suspected in individuals presenting distinctive facial features, a behavioral phenotype
and sleep disturbance. Initial clinical suspicion of the disorder is confirmed by the presence of
a microdeletion in the p11.2 region of chromosome 17 or a mutation in the RAI1 gene. The
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unique SMS behavioral phenotype including sleep disturbance, a hoarse voice, characteristic
hands and feet, excellent long-term memory, good ability and focus with computers, self-injury
scars and typical facial features are important clues to the diagnosis. Because SMS will rarely
be the only possible clinical diagnosis, exams are key to diagnosis.
SMS diagnosis is confirmed by detecting 17p11.2 deletion using classic cytogenetic analysis,
molecular cytogenetic analysis, or molecular genetic methods [20].
Cytogenetic analysis by GTG banding at the 550 band level or higher can detect deletions of
approximately 4Mb, which account for 70% of the cases. However fluorescent in situ hybrid‐
ization (FISH) using an RAI1-specific probe is the most frequently used technique [20, 22,
43-44] (Fig.8 and Fig. 9).
Figure 8. GTG banding of metaphase chromosomes showing the normal chromosome 17 (a) and deleted chromo‐
some 17 (b). Courtesy of the Cytogenetics Laboratory - SAG / IBB-UNESP-Botucatu, SP-BRAZIL
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Figure 9. Metaphase FISH using the probe in the Smith-Majenis Cytocell ® (RAI 1 and Flii) / Miller-Dieker. The red area
shows the control the green gene responsible for SMS. Courtesy of the Cytogenetics Laboratory - SAG / IBB-UNESP-
Botucatu, SP-BRAZIL
Beyond these cytogenetic methods, methods that require only DNA for analysis are newer, cost-
efficient, and can be used in a large number of patients at the same time. Additionally, MLPA or
qPCR can identify smaller deletions at a higher resolution than FISH or G-banding [45].
6. Differential diagnosis
The differential diagnosis for SMS includes [13, 44].
• 1q36 deletion syndrome
• 9q34 deletion syndrome
As the clinical characteristics of SMS and these syndromes overlap, specific FISH tests are
required for establishing a final diagnosis
• 22q11.2 deletion syndrome: velopharyngeal abnormalities and facial characteristics
differentiate this syndrome from SMS
Intellectual and Behavioral Disabilities in Smith — Magenis Syndrome
http://dx.doi.org/10.5772/55721
73
• Down syndrome: despite having several ovelapping features with SMS, Down syndrome
can be diagnosed by simple karyotype analysis
• Williams-Beuren syndrome (WBS): SMS and this syndrome show opposing behavioral
characteristics. While WBS patients are overfriendly, loquacious and frequently smiling,
SMS individuals are shy, aggressive and restless
• Prader-Willi syndrome (PWS): although obesity may be present in both PWS and SMS, it is
always of the morbid type in PWS patients:
• Sotos syndrome (SS): in SS patients, bone age is advanced while in SMS it is normal.
7. Treatment of manifestations
Patients  with  SMS  present  functional  disturbances  (obesity,  sleep  disturbances)  and
behavioral  abnormalities  (aggression,  self-injury)  which  have  prompted  attempts  to
medically  treat  these  alterations.  Due  to  the  low  frequency  of  SMS,  classical  placebo-
controlled prospective clinical drug trials have not been feasible. Clinical experience to date
indicates that no drug is effective in alleviating any SMS symptoms in more than 60% of
cases. There are a number of anecdotal reports of successful treatments, however many of
unsuccessful treatments are likely unreported.
A review of pharmacological treatments with psychotropic drugs in patients with SMS was
reported [46]. The medications were grouped into seven main categories: [1] stimulants; [2]
antidepressants; [3] antipsychotics; [4] hypnotics; [5] mood stabilizers; [6] alpha 2 agonists; [7]
and benzodiazepines. The stimulant category included methylphenidate, amphetamines, and
others (e.g., pemoline). Antidepressants were subdivided into selective serotonin reuptake
inhibitors (SSRIs), tricyclics (TCA), and others. The antipsychotic category was divided into
typical and atypical. The hypnotic category included melatonin, diphenhydramine,and others.
Mood stabilizers included ithium and anticonvulsants used for mood stabilization. Clonidine
and guanfacine were grouped under alpha 2 agonists and all benzodiazepines were grouped
together. The beta-blockers category was excluded due to a small number of reports. The study
was conducted using medical histories of 62 patients with SMS. This study concluded that no
consistent results were observed for any medicine or drug group, although the study did not
exclude any of the drugs used.
Another elegant work [47,48] tested the effect of administration of B1-adrenergic antago‐
nists  together  with  melatonin  in  10  patients  with  SMS,  in  an  attempt  to  improve  the
circadian disturbances.  These authors concluded that the administration of acebutolol  in
the  morning and melatonin  in  the  early  evening allowed the  biological  clock  reset  and
restore the normal rhythm of melatonin in SMS patients. The patients had improvements
in sleep, diminution of naps during the day, with a higher state of attention and diminu‐
tion of aggressive behavior.
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8. Conclusions
Significant overlap between SMS’s clinical features with other similar syndromes does makes
it very difficult establish a clinical diagnosis. However, the uniqueness of the behavioral
features of this condition should lead health care providers to request specific FISH testing.
Treatment for SMS is merely relies on managing the symptoms. Individuals with SMS often
require several forms of support, including physical therapy, occupational therapy, speech
therapy, and particularly behavioral therapy, which are most effective if started early in life.
Therefore, having an early diagnosis can help guide a person’s health care through life, and
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